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(PF), and perivascular fat (PVF) are specific vis‑
ceral fat depots whose role in cardiovascular dis‑
eases is well established.5 Epicardial fat is embry‑
ologically different from other depots; it has no 
anatomical boundaries with the heart muscle or 
coronary arteries.5 Recent studies have suggested 
its active paracrine and endocrine role in coronary 
artery disease (CAD).6-8 The pathophysiological 
INTRODUCTION Obesity and diabetes (DM) are 
common disorders that increase cardiometabol‑
ic risk and can lead to cardiovascular diseases.1,2 
Precise evaluation of cardiovascular risk related 
to obesity and DM depends on the quantity, dis‑
tribution, and location of body fat and the func‑
tion of adipocytes in fat depots as well as in the 
entire body.3,4 Epicardial fat (EF), paracardial fat 
ORIGINAL ARTICLE
Epicardial, paracardial, and perivascular 
fat quantity, gene expressions, and serum 
cytokines in patients with coronary artery 
disease and diabetes
Maciej Haberka1, Grzegorz Machnik2, Adam Kowalówka3, Małgorzata Biedroń1, 
Estera Skudrzyk2, Bożena Regulska ‑Ilow4, Grzegorz Gajos5, Robert Manka6, 
Marek Deja3, Bogusław Okopień2, Zbigniew Gąsior1
1  Department of Cardiology, School of Health Sciences, Medical University of Silesia, Katowice, Poland
2  Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
3  Department of Cardiac Surgery, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
4   Division of Dietetics, Wroclaw Medical University, Wrocław, Poland
5  Department of Coronary Disease and Heart Failure, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, Kraków, Poland
6  Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
Correspondence to:
Maciej Haberka, MD, PhD, 
Department of Cardiology, 
School of Health Sciences, 
Medical University of Silesia, 
ul. Ziołowa 45/47, 40-635 Katowice, 
Poland, phone: +48 32 252 74 07, 
email: mhaberka@op.pl
Received: June 30, 2019.
Revision accepted: August 31, 2019.
Published online: September 3, 2019.
Pol Arch Intern Med. 2019; 
129 (11): 738-746
doi:10.20452/pamw.14961
Copyright by Medycyna Praktyczna, 
Kraków 2019
KEY WORDS
adipose tissue 
dysfunction, coronary 
artery disease, 
diabetes, epicardial 
fat, perivascular fat
EDITORIAL 
by Nosalski, Alsheikh, 
Guzik, see p. 733
ABSTRACT
INTRODUCTION Obesity and diabetes mellitus (DM) are common disorders that increase cardiovascular 
risk and lead to coronary artery disease (CAD).
OBJECTIVES The aim of our study was to assess the link between epicardial fat (EF) volume and para‑
cardial fat (PF) volume, relative expressions of several genes in epicardial, paracardial, and perivascular 
fat and corresponding serum cytokines in patients with CAD in relation to DM.
PATIENTS AND METHODS A total of 66 consecutive patients (33 with DM) with multivessel CAD were 
included. We obtained cardiac magnetic resonance, serum cytokines levels, and their relative mRNA ex‑
pressions in EF, PF, and perivascular fat samples of the following: adrenomedullin (ADM), fibroblast growth 
factor 21 (FGF21), transforming growth factor β (TGFβ), phospholipid transfer protein (PLTP), receptor for 
advanced glycation endproducts (RAGE), thrombospondin 1 (THSB1), and uncoupling protein 1 (UCP1).
RESULTS There were no differences in the anthropometric parameters or fat depots, except for higher 
epicardial fat volume in patients with DM (mean [SD], 105.6 [38.5] ml vs 84 [29.2] ml; P = 0.02). Patients 
with DM exhibited a significantly increased RAGE expression in EF (median [Q1–Q3], 0.17 [0.06–1.48] 
AU vs 0.08 [0.02–0.24] AU, P = 0.03). Diabetes was also associated with increased expression of ADM 
in EF and PF and decreased expression of FGF21 compared with patients without DM.
CONCLUSIONS Patients with multivessel CAD and DM revealed increased volume and more dysfunc‑
tional profile of gene expressions in EF and significantly decreased expression of cardioprotective FGF21.
ORIGINAL ARTICLE Epicardial fat in coronary artery disease and diabetes 739
Patients were recruited and completed 
the study at the Department of Cardiology at the 
Medical University of Silesia. The study proto‑
col was approved by the local Medical Universi‑
ty of Silesia Ethic Committee (no. KNW/0022/
KB1/127/I/13/14) and all patients gave their writ‑
ten informed consent to the protocol. This work 
was supported by the research non ‑commercial 
grant from Medical University of Silesia (KNW‑
‑1‑085/N/5/0, KNW ‑1‑016/K/8/K) and Polish 
Cardiac Society (Servier 2016).
Clinical characteristics Hyperlipidemia, hyper‑
tension, DM, and metabolic syndrome were iden‑
tified based on prior diagnosis or current treat‑
ment and defined according to the guidelines.10 
Overweight and obesity were classified accord‑
ing to body mass index ([BMI], calculated as fol‑
lows: BMI = body mass [kg] / height [m²]) as 
normal weight (18.5–24.9 kg/m²), overweight 
(25.0–29.9 kg/m²), and obesity (≥30.0 kg/m²), 
divided into class 1 (30.0–34.9 kg/m²), class 2 
(35.0–39.9 kg/m²), and class 3 (≥40.0 kg/m²). 
Waist circumference (midpoint between the low‑
est rib and the iliac crest) was measured with 
a tape measure at the end of expiration. Addition‑
al measures were also obtained: neck circumfer‑
ence just below the laryngeal prominence, mid‑
point thigh circumference, and midpoint arm cir‑
cumference, and the sum of 3 parameters was cal‑
culated. Skinfolds measured the thickness of skin 
and subcutaneous fat with the use of the equa‑
tions of Jackson and Pollock.11 The bioelectric 
impedance analysis (Bodystat 1500, Bodystat, 
Isle of Man, United Kingdom) was used to mea‑
sure the patients’ body composition with body 
fat percentage.
Ultrasound (3.5 MHz transducer, GE Vivid 9, 
GE Healthcare, Milwaukee, Wisconsin, United 
States) was used in all patients to obtain the in‑
dex measure of visceral abdominal fat.12 All par‑
ticipants completed a detailed dietary assessment 
with a country ‑specific, validated food frequen‑
cy questionnaire.13 Afterwards, it was converted 
into nutrients with a country ‑specific database 
used in the multicenter PURE (Prospective Ur‑
ban Rural Epidemiology) study.14
Cardiac magnetic resonance imaging of epicardi-
al and paracardial fat We quantified EFV and 
PFV on electrocardiogram ‑gated cine im‑
ages acquired on 1.5T system (GE Optima 
MR450w, GE Healthcare) with a dedicated car‑
diac coil using a steady ‑state free precession se‑
quence. The scan parameters used were time to 
echo / time of repetition, 1.9/4.3 ms, slice thick‑
ness of 8 mm (no interslice gap). EF and PF were 
defined as the particular adipose tissue in end‑
‑diastole (EF, tissue between myocardium and 
visceral layer of pericardium and PF, all the fat 
surrounding the heart outside the EF) along 
the walls of the right and left ventricles start‑
ing from the basal segments (level of atrioven‑
tricular valves) up to the apex area.
mechanisms responsible for the balance between 
protective and proatherosclerotic effects of EF are 
also not yet understood. Therefore, we aimed to 
evaluate the link between EF volume (EFV) and 
PF volume, relative expressions of several genes 
in EF, PF, and PVF and corresponding serum cy‑
tokines in patients with multivessel CAD in rela‑
tion to DM. We hypothesized that EF, PF, and PVF 
samples obtained from patients with DM would 
have a more proatherogenic gene expression pro‑
files, which would be associated with serum cy‑
tokines and increased fat volumes.
PATIENTS AND METHODS Study population A to‑
tal of 66 consecutive patients (aged 45–80 years) 
with multivessel CAD scheduled for elective cor‑
onary artery bypass grafting (CABG) in the De‑
partment of Cardiac Surgery in Medical University 
of Silesia in Katowice were included in the study 
after consideration of exclusion criteria. Given 
the aim of the study, the main exclusion criteria 
were as follows: acute coronary syndrome at the 
index hospitalization and in prior 6 months, prior 
thorax surgery, indications for any other type of 
cardiac surgery, significant heart valve dysfunc‑
tion, congestive heart failure, left or right ventri‑
cle systolic dysfunction, significant diastolic dys‑
function, infectious diseases in prior 2 months, 
chronic inflammatory diseases, neoplastic diseas‑
es (diagnosis and / or treatment in prior 5 years), 
significant renal or liver dysfunction, any anti‑
‑inflammatory or anti ‑infective medicines in pri‑
or month, secondary causes of obesity, specific in‑
terventions aimed at obesity in prior 12 months, 
a 10% unintentional weight loss in prior 3 months 
or risk of malnutrition (Mini Nutritional Assess‑
ment score <12 points),9 a very poor image quali‑
ty or contraindications to cardiac magnetic reso‑
nance (CMR), known genetic predisposition for 
cardiovascular diseases.
Study protocol The study protocol included: a de‑
tailed clinical assessment (Supplementary mate‑
rial, Table S1) with evaluation of anthropomet‑
ric parameters and adiposity, CMR performed 
for the volumetry of fat depots, peripheral ve‑
nous blood samples for serum levels of cytokines, 
and fat samples obtained during cardiac surgery.
WHAT’S NEW?
We present a comprehensive study of epicardial, paracardial, and perivascular 
fat depot quantification, genes expressions, and corresponding serum cytokines 
in patients with and without diabetes (DM). Despite similar anthropometric 
parameters of obesity, patients with DM had increased epicardial fat volume 
with no differences in other fat depots. Diabetes is associated with decreased 
mRNA relative expression of FGF21, increased expression of ADM and RAGE 
in epicardial fat suggesting their unique role in atherosclerotic pathway in DM 
in contrast to TGFβ, PLTP, THSB1, or UCP1. Finally, serum cytokines levels do 
not follow the relative mRNA expressions of the corresponding cytokines in fat 
depots, which limits their potential role as markers of adipose tissue dysfunction.
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Human glyceraldehyde 3 ‑phosphate dehydro‑
genase gene (GAPDH) was used as a reference 
for quantitative analysis, and 2 μl of the reverse 
transcription reaction mixture (ie, an equivalent 
of 10 ng of total RNA) was used as a template 
for QPCR. Real ‑time QPCR was performed using 
SYBR Select Master Mix (Thermo Fisher Scientif‑
ic) in a total volume of 20 μl that contained 200 
nm of each (forward and reverse) gene‑specific 
primers. All primers for QPCR were derived from 
PrimerBank database (https://pga.mgh.harvard.
edu/primerbank/).16 All primer pairs spanned 
the intron / exon boundary to exclude the possi‑
bility of false ‑positive results from genomic DNA. 
Reactions were performed using Roche LightCy‑
cler 480 Instrument II (Roche Diagnostics, War‑
saw, Poland) with a thermal profile set as fol‑
lows: 94°C/3 min then 35 cycles of 94°C/30 s, 
58°C/30 s, 72°C/45 s. The specificity of each re‑
action was confirmed by a melting ‑curve analy‑
sis. The increase in fluorescence was measured in 
real time and threshold cycle (Ct) values were ob‑
tained. The target gene Ct number was normal‑
ized to the endogenous reference GAPDH and 
the formula 2(–ΔΔCt) was used to calculate relative 
(to subcutaneous fat) gene expression.17
Statistical analysis The results presented in 
the manuscript or tables are expressed as means 
(SD) for normally distributed variables, medi‑
ans (quartiles Q1–Q3) for nonnormal distri‑
bution, or number (percentage). The  distri‑
bution was tested for the normality with the 
Kolmogorov–Smironov test. Baseline clinical 
parameters and the measures were compared 
between the subgroups using the t test for nor‑
mally distributed continuous variables; in case 
of nonnormal distribution, the Mann–Whitney 
test was used. Associations between parame‑
ters were assessed using the Pearson or Spear‑
men rank correlation analysis, depending on 
the parametric or nonparametric distribution 
of variables. A P value of less than 0.05 was con‑
sidered significant. Statistical analysis was per‑
formed using the Statistica software (version 
10.0, Stat Soft, Warsaw, Poland)
RESULTS Study group characteristics Our study 
group included 66 patients (mean [SD] age, 65.6 
[7.2] years; men, 76%) with preserved left ven‑
tricular systolic function and a multivessel CAD 
scheduled for CABG. Patients clinical character‑
istics, adiposity, ultrasound, and CMR indices of 
fat depots are shown in Supplementary materi‑
al, Table S1. In brief, the study patients had sev‑
eral cardiovascular risk factors, including hyper‑
tension and dyslipidemia in all individuals and 
the following: overweight (51%), obesity (38%), 
DM (50%), nicotinism (48%).
Diabetes and multivessel coronary artery disease 
The patients were divided into subgroups based 
on whether they had DM or not (TABLE 1). Patients 
with and without DM revealed very similar clinical 
Adipose tissue areas were traced manually us‑
ing short ‑axis images on the zoomed images pro‑
ceeding through the slices from the atrioventricular 
valves to the left ventricular apex and were multi‑
plied by the slice thickness (Supplementary mate‑
rial, Figure S1). Afterwards, EFV and PFV were cal‑
culated using the summation of the disc method.
Blood collection Blood samples were collected 
from all the patients prior to cardiac surgery. 
Afterwards, serum was obtained by centrifu‑
gation and the samples were stored in aliquots 
at –80°C. The serum concentrations of the fol‑
lowing cytokines (enzyme ‑linked immunosorbent 
assay [ELISA] kits) were performed according to 
the manufacturer’s protocols: proadrenomedullin 
(ADM, Cucabio Biotech Co, Houston, Texas, Unit‑
ed States), fibroblast growth factor 21 (FGF21, 
BioVendor, Brno, CZ), transforming growth fac‑
tor β (TGFβ, Diaclone SAS, Besancon, France), 
phospholipid transfer protein (PLTP, Cloud ‑Clone 
Corp, Houston, Texas, United States), thrombo‑
spondin 1 (THSB1, Cloud ‑Clone Corp, Houston, 
United States), uncoupling protein 1 (UCP1, Cus‑
abio Biotech Co, Houston, Texas, United States).
Adipose tissue collection The adipose tissue sam‑
ples were taken in the beginning of CABG proce‑
dure in tissues that had not been previously trau‑
matized. All fat samples were taken in the same 
order and in the same locations in all patients: 
1) subcutaneous fat at sternotomy; 2) PF within 
thorax; 3) PVF from internal mammary artery; 
and 4) EF adjacent to the proximal right coro‑
nary artery (Supplementary material, Figure S2). 
The biopsy specimens were immediately stored 
at –80°C until further analysis.
RNA extraction and reverse transcriptase -polymerase 
chain reaction RNA was extracted using the 
phenol ‑chloroform method with TRI reagent 
(MRC Inc., Cincinnati, Ohio, United States).15 
Adipose tissue samples (200 mg each) were put 
into 2 ml Eppendorf ‑type tubes directly into 1 ml 
of TRI reagent, which contained 5 μl of precipita‑
tion carrier reagent (MRC Inc.). Thereafter, sam‑
ples were homogenized by means of a rotor / sta‑
tor, hand ‑held homogenizer (IKA ‑Werke GmbH & 
Co KG, Staufen, Germany). All subsequent steps 
were performed according to the manufacturer’s 
instruction. Finally, purified RNA was resolved in 
100 μl of nuclease ‑free water. RNA concentration 
was determined spectrophotometrically by mea‑
suring the absorbance at 260 nm (BioPhotome‑
ter, Eppendorf, Hamburg, Germany). A 500 ng of 
total RNA was reverse transcribed using the High 
Capacity cDNA Reverse Transcription Kit (Ther‑
mo Fisher Scientific, Warsaw, Poland) in a reac‑
tion volume of 20 μl. Finally, the reverse tran‑
scription reaction mixture was diluted at a ratio of 
1:4 with nuclease ‑free water. Quantitative analy‑
sis of the above ‑mentioned genes was carried out 
by a 2 ‑step reverse transcriptase real ‑time quan‑
titative polymerase chain reaction assay (QPCR). 
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There were significant associations of relative 
expressions of FGF21, RAGE, or ADM in different 
fat depots (Supplementary material, Table S2).
All other associations not mentioned above, in‑
cluding gene expressions of all 3 fat depots and 
serum concentrations of the corresponding cy‑
tokines were not significant (data not shown).
DISCUSSION Our study evaluated the quantity 
and quality of EF, PF, and PVF depots in relation 
to DM in patients with severe CAD. First, despite 
similar anthropometric parameters of obesity, pa‑
tients with DM had increased EFV with no dif‑
ferences in other fat depots. Second, DM is as‑
sociated with decreased mRNA relative expres‑
sion of FGF21 (EF and PF), increased expression 
of ADM (EF and PF) and increased expression of 
RAGE in epicardial adipose tissue suggesting their 
unique role in atherosclerotic pathway in DM in 
contrast to TGFβ, PLTP, THSB1, or UCP1. Finally, 
serum levels of cytokines do not follow the rela‑
tive mRNA expressions of the corresponding cy‑
tokines in fat depots, which limits their poten‑
tial role as markers of adipose tissue dysfunction.
To the best of our knowledge, this is the first 
study providing a comprehensive CMR assess‑
ment and profiles of gene expressions in 3 fat de‑
pots with serum concentrations of correspond‑
ing cytokines in multivessel CAD, which suggests 
unique pathophysiological findings for DM.
Fat depot quantity In our study, patients with 
multivessel CAD and DM showed significantly 
increased EF compared with those without DM, 
which is in line with previous reports.18-20 None 
of the other fat depots or anthropometric param‑
eters of obesity revealed any differences between 
both subgroups. There are several studies focused 
on histological analysis of fat samples obtained 
mainly in larger visceral fat depots or individu‑
als with severe obesity in relation to obesity or 
metabolic dysfunction.21-23 Increased EFV results 
from various depot ‑specific histological findings, 
including a simple hypertrophy and hyperplasia 
in response to excess energy in obesity to inflam‑
matory cells infiltration and different patterns of 
fibrosis in DM and dyslipidemia.22 The increase 
in adiposity is associated with enhanced inflam‑
mation23 and adipocyte size, and distribution is 
also linked with insulin resistance and DM, but 
evidence regarding causative associations is lim‑
ited.24 Patients in our study were in various BMI 
categories and some EF samples obtained from 
lean individuals were not enough for additional 
histological study. EFV showed only moderate as‑
sociations with BMI and waist circumference and 
a moderate association with serum TGFβ, which 
was found in all patients. Moreover, EFV was in‑
versely correlated with UCP1 expression, especial‑
ly in patients with DM. It suggests that the in‑
creased quantity of EF is more specific for meta‑
bolic disturbances, including DM, and not related 
to serum cytokines or mRNA genes expression in‑
volved in atherogenesis. UCP1 is a major marker 
characteristics, which allowed us to search for 
any differences in the quantity of fat depots, lo‑
cal mRNA genes expressions, and corresponding 
serum cytokines concentrations.
There were no differences in the prevalence 
of cardiovascular risk factors, diet, clinical pa‑
rameters of obesity and fat depots, except for 
EFV, which was increased in patients with DM 
(mean [SD], 105.6 [38.5] vs 84 [29.2] ml; P = 0.02) 
(TABLE 1).
Serum profile of atherogenic cytokines Serum 
PLTP levels were significantly higher in patients 
with DM compared with patients without DM 
(mean [SD], 18.2 [12.5–31.4] vs 12.9 [8.5–22] 
µg/ml; P=0.03). However, serum concentrations 
of the following cytokines were similar in both 
subgroups: ADM, FGF21, TGFβ, THBS1, UCP1 
(TABLE 2).
Relative mRNA genes expressions in epicardial, para-
cardial, and perivascular fat depots Patients with 
DM showed a significantly higher RAGE expres‑
sion in EF (mean [SD], 0.17 [0.06–1.48] AU vs 
0.08 [0.02–0.24] AU; P = 0.03). Diabetes was also 
associated with increased expression of ADM in 
EF (mean [SD], 1 [0.46–2.2] AU vs 0.51 [0.14–1] 
AU; P = 0.03) and PF (mean [SD], 1 [0.22–0.6] 
AU vs 0.35 [0.13–0.9] AU; P = 0.03). Moreover, 
the expression of FGF21 in EF was significantly de‑
creased in patients with DM compared with those 
without DM (mean [SD], 2.6 [0.4–5.1] AU vs 4.2 
[1.1–22.7] AU; P = 0.04) and PF (1.43 [0.9–3.2] 
AU vs 14.2 [0.55–27.8] AU; P = 0.04). However, 
there were no differences in relative expressions 
of TGFβ, PLTP, THSB1, and UCP1 between both 
subgroups (TABLE 3).
Given that patients with DM had significantly 
increased EF depot (EFV), all the relative expres‑
sions of genes obtained from the EF samples were 
indexed to EFV and compared (TABLE 4).
A comprehensive correlation analysis was per‑
formed in the study group and subgroups with 
and without DM. EFV was associated with BMI 
(DM [+], r = 0.4; P = 0.03 and DM [–], r = 0.4; 
P = 0.02) and waist circumference (DM [+], 
r = 0.4; P = 0.02 and DM [–], r = 0.4; P = 0.04). 
Paracardial fat volume was associated with BMI 
(DM [+], r = 0.55; P = 0.02 and DM [–], r = 0.45; 
P = 0.01) and waist circumference (DM [+], r = 0.5; 
P = 0.002 and DM [–], r = 0.4; P = 0.02).
Among serum levels of cytokines, TGFβ was 
associated with EFV in patients with (r = 0,5; 
P = 0.004) and without DM (r = 0.3; P = 0.03). 
Moreover, relative expression of UCP1 in EF was 
associated with EFV in patients with DM (r = –0.5; 
P = 0.03) and without DM (r = –0.4; P = 0.05). 
The expression of ADM showed association with 
EFV / PFV ratio in patients with DM (r = 0.6; 
P <0.001) and a tendency toward association in 
patients without DM (r = 0.3; P = 0.04). The CMR 
quantity parameters of fat depots did not reveal 
associations with serum cytokines or mRNA ex‑
pressions in corresponding fat depots.
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TABLE 1 Clinical characteristics, anthropometric parameters, and adiposity in patients with and without diabetes
Parameter                      Multivessel coronary artery disease                               P value
Diabetes (+) (n = 33) Diabetes (–) (n = 33)
Clinical characteristics
Age, y, median (IQR) 65 (61–73.5) 65 (58–69) 0.17
Fasting plasma glucose, mg/dl, mean (SD) 123.3 (9.3) 89.2 (9.9) <0.001
Glycated hemoglobin, %, mean (SD) 7.8 (0.8) 5.95 (0.4) <0.001
Hypertension, n (%) 33 (100) 33 (100) 1.0
Dyslipidemia, n (%) 33 (100) 33 (100) 1.0
Total cholesterol, mg/dl, mean (SD) 154 (38.3) 155.6 (33.7) 0.86
LDL cholesterol, mg/dl, mean (SD) 86.5 (32.4) 90.1 (28.9) 0.64
HDL cholesterol, mg/dl, mean (SD) 44.9 (12) 42.7 (9.8) 0.42
Triglycerides, mg/dl, median (IQR) 103 (84.7–141.7) 108 (84–105) 0.68
Smoker or ex ‑smokera, n (%) 18 (54) 14 (42) 0.33
Risk factorsb, median (IQR) 6 (6–7) 4 (4–6) <0.001
Number of vessels with CADc, median (IQR) 3 (2.75–3) 3 (2–3) 0.16
LVEDV, ml, mean (SD) 139 (35) 154 (32.5) 0.24
LV mass, g, mean (SD) 131 (37) 136.2 (32) 0.63
LVEF, %, median (IQR) 58.5 (53–60) 55 (53.2–60) 0.44
Anthropometric parameters
Overweight, n (%) 15 (45) 19 (57) 0.33
Obesity, n (%) 14 (42) 11 (33) 0.45
Weight, kg, median (IQR) 85 (77–95) 81.5 (73–92) 0.28
Body surface area, m², median (IQR) 1.94 (1.8–2.1) 1.87 (1.6–2.1) 0.12
Body fatd, % 33.7 (8.4) 30.27 (6.5) 0.11
Body mass index, kg/m² 29.9 (4.8) 29.2 (4.3) 0.47
WC: W >80 or M >94, n (%) 30 (90) 29 (87) 0.72
WC, cm, median (IQR) 102 (97.5–112) 98 (92.5–111) 0.33
Neck + thigh + arm circumference, cm, median (IQR) 116 (109–127) 116 (105–125) 0.62
3 ‑sites skinfold thickness, mm, median (IQR) 73 (63–79) 65 (59–70.5) 0.07
Adiposity
Abdominal visceral FAT, mm, median (IQR) 49 (33.2–65) 41 (28.7–56) 0.52
Epicardial fat volume, ml, mean (SD) 105.6 (38.5) 84 (29.2) 0.02
Pericardial fat volume, ml, median (IQR) 121.2 (94.2–186.2) 124.3 (84.5–161.7) 0.91
Epi ‑to ‑pericardial fat ratio, mean (IQR) 0.83 (0.59–1.1) 0.64 (0.53–0.84) 0.07
Thorax subcutaneous fat index, median (IQR) 100 (77.6–120) 95 (85.5–108) 0.54
Diet, median (IQR)
Total energy intake, kcal 1597 (1156–2318) 1631 (1317–2043) 0.91
Carbohydrates, g 205 (144–264) 216 (163–251) 0.54
Lipids, g 59.4 (43–100) 54.5 (42–69) 0.36
Proteins, g 67 (47–99) 61 (53–74) 0.62
Cholesterol, mg 239 (148–334) 211 (153–293) 0.32
n ‑3 PUFA, g 1.6 (1–2.1) 1.4 (1–1.9) 0.41
n ‑6 PUFA, g 8.4 (4.8–9.4) 7.2 (5–8.9) 0.52
a Current smoking or smoking in the past for at least 1 year
b Risk factors: male sex, age >55 years old, hypertension, hyperlipidemia, obesity, type 2 diabetes, chronic kidney disease, smoking
c Number of coronary arteries with ≥50% stenosis
d Body fat percentage assessed by bioelectrical impedance method
SI conversion factors: to convert fasting plasma glucose to mmol/l, divide by 18; cholesterol to mmol/l, multiply by 0.02586.
Abbreviations: CAD, coronary artery disease; HDL, high ‑density lipoprotein; IQR, interquartile range; LDL, low ‑density lipoprotein; LV, left ventricular; 
LVEDV, left ventricular end ‑diastolic volume; LVEF, left ventricular ejection fraction; M, men; PUFA, polyunsaturated fatty acid; W, women; WC, waist 
circumference
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no significant association between UCP1 expres‑
sion and EFV or DM.
Epicardial fat genes expressions Epicardial fat 
is a unique depot with several local and system‑
ic effects.3 We aimed to assess the associations 
between various pro‑ and antiatherogenic cyto‑
kines that had the most limited evidence from 
previous studies.5 Our study is the first to show 
that FGF21 expression in visceral fat depots of 
patients with multivessel CAD and DM is signif‑
icantly lower compared with individuals without 
of brown adipose tissue (BAT), which is also in‑
volved in rapid thermogenesis and it was also 
found in EF among adults.25 Our results showed 
no differences in UCP1 expression in EF between 
patients with and without DM, which suggests 
that there is no difference in BAT ‑like phenotype 
in DM.26 An inverse relation between EF expres‑
sion of UCP1 and EFV may be a result of a sim‑
ple compensatory mechanism driven by a de‑
mand for thermogenesis.25 However, evidence 
on UCP1 expression in EF in relation to risk fac‑
tors and EFV is ambiguous. Sacks et al27 showed 
TABLE 2 Serum cytokines in patients with and without diabetes
Parameter Multivessel coronary artery disease P value
Diabetes (+) Diabetes (–)
Proadrenomedullin, pmol/l 3.3 (1.7–4.8) 2.4 (1.6–4.2) 0.51
Fibroblast growth factor 21, pg/ml 209 (126–341) 212 (73–328) 0.42
Transforming growth factor β, pg/ml 6259 (6070–6826) 6229 (6028–7174) 0.73
Phospholipid transfer protein, µg/ml 18.2 (12.5–31.4) 12.9 (8.5–22) 0.03
Thrombospondin 1, ng/ml 1537 (1312–1570) 1540 (1444–1567) 0.92
Uncoupling protein 1, pg/ml 352.2 (184–585) 299.2 (107–560) 0.45
Data are presented as median (interquartile range).
TABLE 3 Relative gene expressions of mRNA in fat depots of patients with and without diabetes
Parameter Multivessel coronary artery disease P value
Diabetes (+) Diabetes (–)
Epicardial fat
Advanced glycation end products rec. 0.17 (0.06–1.48) 0.08 (0.02–0.24) 0.03
Proadrenomedullin 1.0 (0.46–2.2) 0.51 (0.14–1) 0.03
Fibroblast growth factor 21 2.6 (0.4–5.1 4.2 (1.1–22.7) 0.04
Transforming growth factor β 0.14 (0.05–0.5) 0.1 (0.03–0.3) 0.31
Phospholipid transfer protein 1.9 (1.1–3.1) 1.4 (0.9–3) 0.35
Thrombospondin 1 0.57 (0.25–1.8) 0.54 (0.2–1.1) 0.61
Uncoupling protein 1 1.5 (0.35–3.9) 2.8 (0.9–5.5) 0.32
Pericardial fat
Advanced glycation end products rec. 0.15 (0.05–0.36) 0.16 (0.03–1.25) 0.61
Proadrenomedullin 1.0 (0.22–0.6) 0.35 (0.13–0.9) 0.03
Fibroblast growth factor 21 1.43 (0.9–3.2) 14.2 (0.55–27.8) 0.04
Transforming growth factor β 0.13 (0.05–0.4) 0.1 (0.04–0.22) 0.32
Phospholipid transfer protein 1.63 (0.77–2.6) 0.95 (0.4–2.1) 0.22
Thrombospondin 1 1.2 (0.55–1.6) 0.75 (0.3–2.1) 0.35
Uncoupling protein 1 0.7 (0.2–3.2) 1.31 (0.8–3.6) 0.15
Periarterial fat (IMA)
Advanced glycation end products rec. 0.04 (0.02–0.1) 0.045 (0.02–0.08) 0.71
Proadrenomedullin 1.0 (0.4–1.8) 0.88 (0.3–1.1) 0.14
Fibroblast growth factor 21 0.8 (0.3–2.1) 1.72 (0.3–9.7) 0.21
Transforming growth factor β 0.23 (0.04–0.44) 0.15 (0.08–0.5) 0.72
Phospholipid transfer protein 1.3 (0.3–2.2) 1 (0.4–2.5) 0.91
Thrombospondin 1 0.72 (0.28–2.25) 0.35 (0.16–1.95) 0.21
Uncoupling protein 1 1.7 (0.9–3.7) 4.76 (0.9–22.2) 0.11
Data are presented as median (interquartile range). Gene mRNA expression in particular fat depot relative to its 
expression in subcutaneous fat (for details, see Patients and methods). All values are given in arbitrary units.
Abbreviations: IMA, internal nammary artery; rec., receptor
POLISH ARCHIVES OF INTERNAL MEDICINE 2019; 129 (11)744
PF and PVF depots compared with those with‑
out DM. Epicardial RAGE expression was not as‑
sociated with the amount of epicardial depot as 
it was reported by Dozio et al39 using echocar‑
diography fat thickness. However, we used a ref‑
erence method of CMR providing EFV, which is 
a much more precise parameter. RAGE may be in‑
volved in atherosclerosis in both DM and other 
conditions,40,41 but our results suggest that it is 
associated with several proatherogenic pathways 
only in patients with multivessel CAD and DM.
ADM was shown to exert some protective ef‑
fects on cardiac ischemia / reperfusion injury, vas‑
cular calcification or inflammation, it is also in‑
volved in obesity ‑related insulin resistance in 
experimental models.42 Iacobellis et al43 showed 
that ADM mRNA expression in EF was lower in 
patients with CAD than in those without CAD. 
Our study group included only patients with mul‑
tivessel CAD and we found that ADM expression 
is upregulated in individuals with DM suggesting 
a compensatory mechanism. Alternatively, low‑
er expression of protective ADM observed in pa‑
tients with DM may be more pronounced in in‑
dividuals without DM.
There were no differences between patients 
with and without DM in mRNA expression of 
TGFβ, PLTP, THSB1 and UCP1. It suggests that 
those cytokines are not unique for coronary ath‑
erosclerosis in DM.
Quality and function of epicardial fat Although all 
study patients had a multivessel CAD, those with 
DM revealed a more pro ‑atherogenic profile of 
fat gene expressions suggesting that a pericor‑
onary fat dysfunction may play a more impor‑
tant role in this subgroup. Our study protocol in‑
volved CMR as a reference method for EF quan‑
tification and other imaging methods may pro‑
vide only an approximate measure of EF. Finally, 
we show that except for UCP1, none of the oth‑
er gene expressions was related to EFV. Howev‑
er, relative gene expressions in EF were not dif‑
ferent (except for tendency for ADM) between 
both subgroups when indexed to EFV. It implies 
that the differences in expressions of most genes 
found in patients with DM may be interrelated 
with the amount of EF.
DM. Decreased expression of FGF21 was found in 
EF and PF depots, which suggests that the lower 
expression of cardioprotective cytokine is a spe‑
cific finding for DM, but not limited to epicardi‑
al (= pericoronary) fat as it is also found in oth‑
er visceral fat depot. There were no differences 
in serum levels of FGF21 between patients with 
and without DM. Our finding suggests that fu‑
ture clinical trials aimed at FGF21 therapy should 
be focused on that subgroup of patients.
Fibroblast growth factors are a family of cyto‑
kines with multiple intracellular, paracrine, and 
endocrine effects on the cardiovascular system 
and metabolic pathways. FGF21 is a new and most 
promising cytokine in this family due to suggest‑
ed cardioprotective role in cardiovascular diseas‑
es, including atherosclerosis.28 Serum FGF21 lev‑
els were found to be increased in obesity, DM, 
metabolic syndrome, dyslipidemia, nonalcoholic 
fatty liver disease, and coronary or peripheral ar‑
tery disease.29 Researchers have speculated that 
increased serum levels of FGF21 may be an early 
biomarker of cardiometabolic dysfunction or it 
may reflect a compensatory cardioprotective re‑
sponse in pathological states.29 Moreover, a grow‑
ing body of evidence suggests that FGF21 is not 
only a cardiovascular marker but it plays some 
cardioprotective role. FGF21 was shown to exert 
lipid ‑lowering effects,30 anti ‑atherosclerotic ef‑
fects,31,32 and cardioprotection in myocardial isch‑
emia / reperfusion injury.33 Moreover, the long‑
‑term treatment of FGF21 was shown to prevent 
diabetic cardiomyopathy.34 Although the liver is 
a major source of serum FGF21, FGF21 pathways 
were also evidenced in adipose tissue35 where 
it improves glucose uptake, lipolysis, oxidative 
capacity, and it affects thermogenic activity of 
BAT.36 The evidence supporting cardiovascular 
and metabolic protective effects encouraged re‑
searchers to test the exogenous FGF21 in ani‑
mal models and therapy in humans in clinical 
trials.37,38
RAGE is a multiligand receptor for advanced 
glycation end products and other peptides, which 
is involved in the inflammatory process, metabol‑
ic dysfunction, and atherosclerosis.39 We found 
that patients with DM have significantly increased 
expression of RAGE in EF with no differences in 
TABLE 4 Relative gene expressions of mRNA in epicardial fat indexed to epicardial fat volume in patients with and 
without diabetes
Parameter Multivessel coronary artery disease P value
Diabetes (+) Diabetes (–)
Advanced glycation end products rec. 0.18 (0.37–0.88) 0.08 (0.02–0.29) 0.13
Proadrenomedullin 1.2 (0.5–2) 0.7 (0.07–1.4) 0.06
Fibroblast growth factor 21 0.72 (0.08–4.1) 2.1 (0.08–21.5) 0.18
Transforming growth factor β 0.06 (0.01–0.2) 0.04 (0.01–0.4) 0.88
Phospholipid transfer protein 1.06 (0.2–2.1) 1.07 (0.13–2.65) 0.66
Thrombospondin 1 0.35 (0.01–0.72) 0.36 (0.06–1.5) 0.65
Uncoupling protein 1 0.27 (0.03–2.3) 1.8 (0.1–5.6) 0.12
Data are presented as median (interquartile range). All values are given in arbitrary units.
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Conclusions and clinical implications Increasing 
prevalence of obesity, DM, and related adipose tis‑
sue dysfunction will be important triggers for car‑
diovascular diseases. Among patients with multi‑
vessel CAD, DM is associated with increased EFV 
and more dysfunctional profile of genes expres‑
sion in EF. The amount of EF and mRNA genes ex‑
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